Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib Consolidation in Advanced NSCLC
NCT00113516Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2005
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoint: Proportion of Subjects Surviving at One Year at 1 year. Started Sep 2005; status: completed.
02
Drugs
sunitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00113516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113516.